240 related articles for article (PubMed ID: 37531417)
1. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract][Full Text] [Related]
2. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.
Jing M; He X; Cai CZ; Ma QZ; Li K; Zhang BX; Yin Y; Shi MS; Wang YS
Biochem Biophys Res Commun; 2023 Nov; 681():218-224. PubMed ID: 37783120
[TBL] [Abstract][Full Text] [Related]
4. Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.
Metz EP; Wilder PJ; Dong J; Datta K; Rizzino A
J Cell Physiol; 2020 Apr; 235(4):3731-3740. PubMed ID: 31587305
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
6. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
9. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.
Simbolo M; Centonze G; Ali G; Garzone G; Taormina S; Sabella G; Ciaparrone C; Mafficini A; Grillo F; Mangogna A; Volante M; Mastracci L; Fontanini G; Pilotto S; Bria E; Infante M; Capella C; Rolli L; Pastorino U; Milella M; Milione M; Scarpa A
ESMO Open; 2022 Feb; 7(1):100308. PubMed ID: 34952268
[TBL] [Abstract][Full Text] [Related]
10. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
12. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers.
Rubin MA; Bristow RG; Thienger PD; Dive C; Imielinski M
Mol Cell; 2020 Nov; 80(4):562-577. PubMed ID: 33217316
[TBL] [Abstract][Full Text] [Related]
13. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
14. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.
Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Manoj P; Donoghue MTA; Won HH; Chan JM; Ciampricotti M; Chow A; Offin M; Chang JC; Ray-Kirton J; Tischfield SE; Egger J; Bhanot UK; Linkov I; Asher M; Sinha S; Silber J; Iacobuzio-Donahue CA; Roehrl MH; Hollmann TJ; Yu HA; Qiu J; de Stanchina E; Baine MK; Rekhtman N; Poirier JT; Loomis B; Koche RP; Rudin CM; Sen T
Cancer Discov; 2021 Dec; 11(12):3028-3047. PubMed ID: 34155000
[TBL] [Abstract][Full Text] [Related]
15. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
16. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P; Zhang Z; Benelli M; Karthaus WR; Hoover E; Chen CC; Wongvipat J; Ku SY; Gao D; Cao Z; Shah N; Adams EJ; Abida W; Watson PA; Prandi D; Huang CH; de Stanchina E; Lowe SW; Ellis L; Beltran H; Rubin MA; Goodrich DW; Demichelis F; Sawyers CL
Science; 2017 Jan; 355(6320):84-88. PubMed ID: 28059768
[TBL] [Abstract][Full Text] [Related]
17. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.
Quintanal-Villalonga A; Taniguchi H; Hao Y; Chow A; Zhan YA; Chavan SS; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Offin M; Ciampricotti M; Ray-Kirton J; Egger J; Bhanot U; Linkov I; Asher M; Roehrl MH; Qiu J; de Stanchina E; Hollmann TJ; Koche RP; Sen T; Poirier JT; Rudin CM
Cancer Res; 2022 Feb; 82(3):472-483. PubMed ID: 34815254
[TBL] [Abstract][Full Text] [Related]
20. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
